Dermatoses of the skin, and their relevance to the early detection of many systemic forms of cancer, are reviewed.
Researchers report on their implementation of a mobile-health tool for monitoring symptoms of treatment toxicity.
August and September 2021 FDA drug approvals include treatments for tick-borne encephalitis, idiopathic hypersomnia, schizophrenia, and atopic dermatitis.
The American Society of Pain and Neuroscience has published a best practice guideline for the management and reduction of cancer-associated pain.
Frequency of alcohol consumption may be more important than the amount of alcohol consumed.
Researchers studied a total of 1903 cases of pediatric melanoma and patients were 54.4% female, the mean age was 12.4 years, and 89.8% were White.
Triple-negative breast cancer comprises 10% to 15% of breast cancers, mostly in women who are premenopausal, Black, and BRCA1 positive.
Researchers outline diagnostic and treatment options for oral leukoplakia including use of carbon dioxide (CO2) laser therapy.
Eight percent drop in screenings at 32 community health centers means about 47,517 fewer mammograms, 242 missed breast cancer diagnoses.
A report examines a newly created role in nursing care for managing patient care during chimeric antigen receptor T-cell therapy in the outpatient setting.
Factors associated with use or nonuse found to be similar between the groups
An appropriate vaccination strategy will follow.
Researchers used latent variable modeling and a patient-centered analytic approach to identify subgroups of patients with distinct chemotherapy-induced nausea profiles.
Finding from a recent study could be used in patient counseling to promote healthier lifestyle choices to reduce the likelihood of prostate biopsy, according to investigators.
An update on the available cancer screening guidelines, benefits/limitations, and risks for cervical, breast, prostate, colon, and lung cancers.
Matched cohort study showed risk greatest for those with primary myelofibrosis, but still high for those with polycythemia vera and essential thrombocythemia.
An analysis of data sought to determine the effect of delays related to fertility preservation on the initiation of treatment and overall survival.
There was no benefit to extending zoledronate treatment beyond 2 years.
Limited or no improvement seen in female breast cancer, cervical cancer, ovarian cancer, and bone and joint sarcomas.
The association was observed with colon cancer but not rectal cancer.